Nektar Therapeutics Loss Contingency Accrual
Nektar Therapeutics (NKTR) had Loss Contingency Accrual of $0 as of 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LossContingencyAccrualAtCarryingValue · last filed 2017-05-10
- 2017-03-31: Loss Contingency Accrual $0.00.
- 2016-12-31: Loss Contingency Accrual $0.00.
- 2015-12-31: Loss Contingency Accrual $0.00.
- 2011-09-30: Loss Contingency Accrual $2.70M.
| Period end | Loss Contingency Accrual |
|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 |
| 2016-12-31 | $0.00 10-Q · filed 2017-05-10 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
| 2011-09-30 | $2.70M 10-Q · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |